Page last updated: 2024-09-04

carbapenems and mk-7655

carbapenems has been researched along with mk-7655 in 22 studies

Compound Research Comparison

Studies
(carbapenems)
Trials
(carbapenems)
Recent Studies (post-2010)
(carbapenems)
Studies
(mk-7655)
Trials
(mk-7655)
Recent Studies (post-2010) (mk-7655)
7,3551475,2771409136

Research

Studies (22)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (13.64)24.3611
2020's19 (86.36)2.80

Authors

AuthorsStudies
Chang, KT; Hirsch, EB; Ledesma, KR; Motyl, MR; Schwartz, MS; Tam, VH1
Ammerman, NC; Kaushik, A; Kreiswirth, BN; Lamichhane, G; Lee, J; Martins, O; Nuermberger, EL; Parrish, NM1
Hsu, AJ; Tamma, PD1
Sfeir, MM1
Bassetti, M; Battaglini, D; Giacobbe, DR; Pelosi, P; Vena, A1
Chahine, EB; Karaoui, LR; Mansour, H; Ouweini, AEL1
Hsieh, YJ; Kao, LT; Lian, SH; Lin, IL; Liu, GH; Lu, PL; Tseng, SP; Wang, HY; Wang, LC; Yang, TY1
Bragantini, D; Carrara, E; Cattaneo, P; Chiamenti, M; Ellis, S; Franceschi, F; Giske, CG; Lodise, T; Menchinelli, G; Piddock, LJV; Righi, E; Sanguinetti, M; Savoldi, A; Scudeller, L; Tacconelli, E1
Horwich-Scholefield, S; Huang, S; Lloyd, T; Pandori, M; Varghese, V; Yette, E1
Arend, LNVS; Bail, L; Ito, CAS; Nogueira, KDS; Tuon, FF1
Chen, L; Chen, T; Fang, R; Liao, W; Xu, C; Zhang, S; Zhou, C; Zhou, T1
Lodise, TP; O'Donnell, JN1
Birgy, A; Bonacorsi, S; Courroux, C; Danjean, M; Gits-Muselli, M; Hobson, CA; Monjault, A1
Findlay, J; Nordmann, P; Poirel, L; Rens, C1
Haines, RR; Hammer, KA; Putsathit, P; Tai, AS1
König, E; Zollner-Schwetz, I1
Carvalhaes, CG; Castanheira, M; Duncan, L; Kimbrough, JH; Mendes, RE; Sader, HS1
Gu, Y; Hu, D; Hu, M; Liang, R; Wang, D; Wang, M; Zhu, M1
DeRyke, CA; Hackel, M; Hilbert, DW; Motyl, M; Young, K1
Lukovic, B; Petrovic, I; Zornic, S1
Ahmed, A; Chryssanthou, E; Davies Forsman, L; Fröberg, G1
Gill, CM; Lee, SY; Nicolau, DP1

Reviews

5 review(s) available for carbapenems and mk-7655

ArticleYear
Defining the Role of Novel β-Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms.
    Journal of the Pediatric Infectious Diseases Society, 2019, Jul-01, Volume: 8, Issue:3

    Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; Boronic Acids; Carbapenems; Cefiderocol; Ceftazidime; Cephalosporins; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Heterocyclic Compounds, 1-Ring; Meropenem; Tazobactam

2019
The role of new antimicrobials for Gram-negative infections in daily clinical practice.
    Current opinion in infectious diseases, 2020, Volume: 33, Issue:6

    Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azabicyclo Compounds; beta-Lactams; Carbapenems; Cefiderocol; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Bacterial; Gram-Negative Bacterial Infections; Humans; Imipenem; Microbial Sensitivity Tests; Polymyxins; Sisomicin; Tazobactam; Tetracyclines

2020
Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli.
    International journal of antimicrobial agents, 2021, Volume: 57, Issue:5

    Topics: Amikacin; Anti-Bacterial Agents; Azabicyclo Compounds; Carbapenems; Ceftazidime; Cephalosporins; Colistin; Drug Combinations; Drug Resistance, Bacterial; Drug Synergism; Drug Therapy, Combination; Fosfomycin; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; In Vitro Techniques; Microbial Sensitivity Tests; Polymyxins; Rifampin; Tazobactam; Tobramycin

2021
New Perspectives on Antimicrobial Agents: Imipenem-Relebactam.
    Antimicrobial agents and chemotherapy, 2022, 07-19, Volume: 66, Issue:7

    Topics: Adult; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Carbapenems; Humans; Imipenem; Microbial Sensitivity Tests; Pneumonia, Bacterial; Pseudomonas aeruginosa

2022
Treatment options for multidrug-resistant Gram-negatives in urinary tract infections.
    Current opinion in urology, 2023, 05-01, Volume: 33, Issue:3

    Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Gram-Negative Bacterial Infections; Humans; Imipenem; Urinary Tract Infections

2023

Other Studies

17 other study(ies) available for carbapenems and mk-7655

ArticleYear
In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:7

    Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Carbapenems; Gram-Negative Bacteria; Imipenem; Klebsiella pneumoniae; Microbial Sensitivity Tests; Models, Theoretical

2012
    Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:3

    Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactams; Boronic Acids; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Mycobacterium abscessus; Mycobacterium Infections, Nontuberculous

2019
Imipenem-relebactam for Treatment of Carbapenem-resistant Gram-negative Bacteria: Where Do We Stand on In Vitro Susceptibility Testing?
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021, 04-26, Volume: 72, Issue:8

    Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Infections; Carbapenems; Colistin; Double-Blind Method; Gram-Negative Bacteria; Humans; Imipenem

2021
Imipenem/cilastatin/relebactam: A new carbapenem β-lactamase inhibitor combination.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2021, 03-31, Volume: 78, Issue:8

    Topics: Adolescent; Adult; Anti-Bacterial Agents; Azabicyclo Compounds; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Humans; Imipenem; Microbial Sensitivity Tests

2021
Activities of imipenem-relebactam combination against carbapenem-nonsusceptible Enterobacteriaceae in Taiwan.
    Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2022, Volume: 55, Issue:1

    Topics: Animals; Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamases; Caenorhabditis elegans; Carbapenems; Drug Combinations; Drug Resistance, Bacterial; Enterobacteriaceae; Escherichia coli; Humans; Imipenem; Microbial Sensitivity Tests; Taiwan

2022
Imipenem-Relebactam Susceptibility and Genotypic Characteristics of Carbapenem-Resistant
    Antimicrobial agents and chemotherapy, 2021, 10-18, Volume: 65, Issue:11

    Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Gammaproteobacteria; Imipenem; Microbial Sensitivity Tests

2021
Activity of imipenem-relebactam and ceftolozane-tazobactam against carbapenem-resistant Pseudomonas aeruginosa and KPC-producing Enterobacterales.
    Diagnostic microbiology and infectious disease, 2022, Volume: 102, Issue:1

    Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Enzymologic; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Tazobactam

2022
In vitro activity of imipenem-relebactam alone and in combination with fosfomycin against carbapenem-resistant gram-negative pathogens.
    Diagnostic microbiology and infectious disease, 2022, Volume: 103, Issue:3

    Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Escherichia coli; Fosfomycin; Humans; Imipenem; Klebsiella pneumoniae; Microbial Sensitivity Tests

2022
Evaluation of the inoculum effect of new antibiotics against carbapenem-resistant enterobacterales.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2022, Volume: 28, Issue:11

    Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Cefiderocol; Humans; Imipenem; Meropenem; Tazobactam

2022
    Antimicrobial agents and chemotherapy, 2022, 10-18, Volume: 66, Issue:10

    Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Drug Combinations; Escherichia coli; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests

2022
Activity of newest generation β-lactam/β-lactamase inhibitor combination therapies against multidrug resistant Pseudomonas aeruginosa.
    Scientific reports, 2022, 10-07, Volume: 12, Issue:1

    Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Carbapenems; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Lactams; Microbial Sensitivity Tests; Monobactams; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam

2022
Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam activities against multidrug-resistant Enterobacterales from United States Medical Centers (2018-2022).
    Diagnostic microbiology and infectious disease, 2023, Volume: 106, Issue:2

    Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Ceftazidime; Drug Combinations; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; United States

2023
In vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam alone or in combination with polymyxin B against carbapenem resistant Acinetobacter baumannii.
    The Journal of antibiotics, 2023, Volume: 76, Issue:9

    Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Carbapenems; Ceftazidime; Drug Combinations; Imipenem; Meropenem; Microbial Sensitivity Tests; Polymyxin B

2023
Relebactam restores susceptibility of resistant Pseudomonas aeruginosa and Enterobacterales and enhances imipenem activity against chromosomal AmpC-producing species: analysis of global SMART 2018-2020.
    BMC microbiology, 2023, 06-13, Volume: 23, Issue:1

    Topics: Anti-Bacterial Agents; Carbapenems; Gammaproteobacteria; Humans; Imipenem; Pseudomonas aeruginosa

2023
In vitro activity of imipenem/relebactam and ceftazidime/avibactam against carbapenem-resistant Klebsiella pneumoniae from blood cultures in a University hospital in Serbia.
    Acta microbiologica et immunologica Hungarica, 2023, Sep-21, Volume: 70, Issue:3

    Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Blood Culture; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Ceftazidime; Colistin; Drug Combinations; Hospitals, University; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Serbia

2023
The
    Antimicrobial agents and chemotherapy, 2023, 10-18, Volume: 67, Issue:10

    Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Drug Combinations; Imipenem; Microbial Sensitivity Tests; Mycobacterium abscessus

2023
Activity of novel β-lactam/β-lactamase inhibitor combinations against serine carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa.
    The Journal of antimicrobial chemotherapy, 2023, Dec-01, Volume: 78, Issue:12

    Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Ceftazidime; Drug Combinations; Imipenem; Lactams; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa

2023